UK/NETHERLANDS â€" A group of pension funds has told pharmaceutical firms they need more information about the industryâ€™s emerging market strategies.
A report co-sponsored by the two schemes, Pharma Futures 3: Emerging Opportunities, said emerging markets could â€œrevitaliseâ€ pharmaceutical industry growth â€“ but said business models needed to change to account for the distribution and pricing realities of emerging markets.
USS â€“ which invests in around two-thirds of the top 16 pharmaceutical firms and has around 6% of its assets invested in the sector â€“ said emerging markets could reinvigorate the earnings of the sector.
But it said the pharmaceutical firms needed to explain how they would achieve this.
Co-head of responsible investment Daniel Summerfield said pharmaceutical firms also needed to develop strategies for providing affordable medicines to the poor in these countries.
He said: "How these firms provide medicines to the very poorest people in emerging markets while continuing to provide to the middle-class in these markets will be critical to their success.â€
APG Investments senior portfolio of health care Martin Eijgenhuijsen said: â€œInnovative and scalable business models can address health care needs for billions of people and will be recognised as a profit centre by investors when proper guidance is provided.â€
Pharma Futures is an initiative between the pharmaceutical industry and its investors to help them understand each others needs and strategies better.
It was founded in 2004 by institutional investors including USS, APG and the Ohio Public Employees Retirement System (OPERS).
As well as USS and APG Investments, the Pharma Futures 3 working group included representatives from organisations including Astra Zeneca, GSK, Novartis and the Bill and Melinda Gates Foundation.
The Pension Protection Fund (PPF) is consulting on proposals to charge a "risk reflective" levy for commercial defined benefit (DB) consolidation vehicles.
The funding gap across FTSE 350 schemes could be slashed by as much as £275bn if schemes look beyond traditional ways of creating value. Victoria Ticha examines how
There will be "many flavours" of defined benefit (DB) consolidators but consolidation will only be the right answer for a minority of schemes, Alan Rubenstein says.
Work and Pensions Committee (WPC) chairman Frank Field has questioned the regulator on what lessons it can learn from the experience of the Kodak Pension Plan No.2 (KPP2).